AgingResearch.NewsJoin free

Cytokinetics

CompanyUnited States

Cytokinetics develops 2 assets, the furthest in phase 3 (omecamtiv mecarbil in heart failure). Mostly small molecule acting on MYH7; based in the United States.

2
Assets
Furthest stage
Phase 3
2
Trials
2
Signals

Pipeline

2

  • omecamtiv mecarbil

    Activates cardiac myosin to increase cardiac contractility and improve systolic function.

    Phase 3, Small molecule, MYH7, heart failure, heart failure with reduced ejection fraction

  • Aficamten

    Inhibits cardiac myosin to reduce excessive contractility in hypertrophic cardiomyopathy.

    Phase 2, Small molecule, MYH7, symptomatic hypertrophic cardiomyopathy

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Trials2
  • Signals2
  • Similar companies6

Intelligence